ANI PHARMACEUTICALS, INC Deferred Income Tax Assets, Net
ANI PHARMACEUTICALS, INC (ANIP) had Deferred Income Tax Assets, Net of $71.50 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-07
- 2026-06-30: Deferred Income Tax Assets, Net $71.50M.
- 2026-03-31: Deferred Income Tax Assets, Net $66.56M.
- 2025-12-31: Deferred Income Tax Assets, Net $69.07M.
- 2025-09-30: Deferred Income Tax Assets, Net $71.40M.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2026-06-30 | $71.50M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $66.56M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $69.07M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $71.40M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $92.03M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $88.49M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $85.11M 10-K · filed 2026-02-27 |
| 2024-09-30 | $67.66M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $89.51M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $87.61M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $90.71M 10-K · filed 2025-02-28 |
| 2023-09-30 | $84.39M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $81.50M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $80.96M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $81.36M 10-K · filed 2024-02-29 |
| 2022-09-30 | $77.34M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $76.59M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $73.54M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $67.94M 10-K · filed 2023-03-09 |
| 2021-09-30 | $60.20M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $58.53M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $52.01M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $51.70M 10-K · filed 2022-03-15 |
| 2020-09-30 | $48.13M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $53.49M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $57.91M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $38.33M 10-K · filed 2021-03-11 |
| 2018-12-31 | $27.96M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |